User started balding at 16 and began treatment at 18, using RU58841, minoxidil, derma rolling, and peptides. After 6 months, they experienced significant hair regrowth and are happy with the results.
Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.
A 28-year-old male is experiencing temple regrowth but crown thinning while using 5mg minoxidil and 0.5mg dutasteride. The shedding phase is seen as a positive sign of treatment effectiveness, with expectations of noticeable improvements around 6 to 12 months.
The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.
RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.
A 36-year-old experienced significant hair regrowth using minoxidil, finasteride, and tretinoin with minimal side effects. He plans to continue the treatment, hoping for more targeted solutions in the future.
A user shared their 3-month hair loss treatment progress using 5% topical Minoxidil, Finasteride tablets, dermastamping, and ketoconazole shampoo. They reported significant improvement, advised consistency, and addressed questions about side effects and application methods.
A 23-year-old male showed hair regrowth after using finasteride and minoxidil daily for three months, with no significant side effects. Others shared their experiences and discussed side effects and photo lighting differences.
A thirty year old's progress with hair loss treatment, which includes finasteride, minoxidil and dermarolling in addition to taking multivitamins with biotin. The user has seen improvement after three months of using this regimen.
A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.
A 28-year-old man with hair loss is seeing regrowth in his temple area after 2 months of treatment with Dutasteride, a 1.5mm Dermaroller, topical Minoxidil, and Biotin supplements. He also notes an unexpected positive side effect of Dutasteride clearing up his light facial acne.
The conversation discusses using RU58841, topical finasteride/minoxidil, MK677, and microneedling as treatments for hair loss. MK677 is mentioned as a growth hormone that improves hair health and recovery from microneedling.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conclusion of the conversation is that the user has made progress in their hair loss with the use of oral finasteride and topical minoxidil. The progress was most significant in the first year, and the user's temples are slowly improving.
The conversation discusses hair regrowth using finasteride, minoxidil, biotin, and vitamin D over three months, with visible results. One person asks about the daily dosage of vitamin D and biotin.
Hair loss can be linked to low testosterone, affecting DHT and estrogen levels. Treatments discussed include increasing testosterone, using Finasteride, and applying estrogen cream.
A user shared progress pictures showing significant hair regrowth after 3 months using a topical foam with 5% Minoxidil and 0.25% Finasteride. They plan to add derma rolling to their routine.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
The user is experiencing hair regrowth after 3.5 months using finasteride, dutasteride, oral minoxidil, dermastamping, and ketoconazole shampoo. They are hopeful about the progress but note that topical minoxidil was ineffective for them.
User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.
A transwoman shared her 11-month progress using hormone replacement therapy (HRT), finasteride, and minoxidil, reporting significant hair regrowth and satisfaction with the results. The discussion included various perspectives on HRT, its effects on hair and sexual function, and personal experiences with similar treatments.
A user shared their positive experience with a hair transplant, using 3,500 grafts, after trying various treatments like Minoxidil, Finasteride, and Dutasteride. They recommend stabilizing hair loss with Finasteride before considering a transplant.
A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.